Relmada Therapeutics Management
Management criteria checks 3/4
Relmada Therapeutics' CEO is Sergio Traversa, appointed in Apr 2012, has a tenure of 13.75 years. total yearly compensation is $1.80M, comprised of 41.7% salary and 58.3% bonuses, including company stock and options. directly owns 1.77% of the company’s shares, worth €4.27M. The average tenure of the management team and the board of directors is 6 years and 6 years respectively.
Key information
Sergio Traversa
Chief executive officer
US$1.8m
Total compensation
| CEO salary percentage | 41.69% |
| CEO tenure | 13.8yrs |
| CEO ownership | 1.8% |
| Management average tenure | 6yrs |
| Board average tenure | 6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2025 | n/a | n/a | -US$56m |
| Jun 30 2025 | n/a | n/a | -US$68m |
| Mar 31 2025 | n/a | n/a | -US$76m |
| Dec 31 2024 | US$2m | US$751k | -US$80m |
| Sep 30 2024 | n/a | n/a | -US$86m |
| Jun 30 2024 | n/a | n/a | -US$87m |
| Mar 31 2024 | n/a | n/a | -US$94m |
| Dec 31 2023 | US$2m | US$701k | -US$99m |
| Sep 30 2023 | n/a | n/a | -US$112m |
| Jun 30 2023 | n/a | n/a | -US$129m |
| Mar 31 2023 | n/a | n/a | -US$144m |
| Dec 31 2022 | US$3m | US$668k | -US$157m |
| Sep 30 2022 | n/a | n/a | -US$153m |
| Jun 30 2022 | n/a | n/a | -US$157m |
| Mar 31 2022 | n/a | n/a | -US$143m |
| Dec 31 2021 | US$36m | US$630k | -US$126m |
| Sep 30 2021 | n/a | n/a | -US$112m |
| Jun 30 2021 | n/a | n/a | -US$86m |
| Mar 31 2021 | n/a | n/a | -US$71m |
| Dec 31 2020 | US$900k | US$600k | -US$59m |
| Sep 30 2020 | n/a | n/a | -US$43m |
| Jun 30 2020 | n/a | n/a | -US$30m |
| Mar 31 2020 | n/a | n/a | -US$23m |
| Dec 31 2019 | US$16m | US$214k | -US$15m |
Compensation vs Market: Sergio's total compensation ($USD1.80M) is above average for companies of similar size in the German market ($USD801.51K).
Compensation vs Earnings: Sergio's compensation has been consistent with company performance over the past year.
CEO
Sergio Traversa (65 yo)
Dr. Sergio Traversa, Pharm D., M.B.A. has been the Chief Executive Officer and a Director of Relmada Therapeutics, Inc. since April 18, 2012. Dr. Traversa served as Interim Chief Financial Officer at Relma...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.8yrs | US$1.80m | 1.77% € 4.3m | |
| Chief Financial Officer | 6yrs | US$993.75k | 1.09% € 2.6m | |
| COO & Director | 1yr | US$872.78k | 0.68% € 1.6m | |
| Chief Accounting & Compliance Officer | 6yrs | US$983.04k | 0.55% € 1.3m | |
| VP & Head of Clinical Operations | 6.8yrs | no data | no data | |
| Chief Medical Officer of Urology | less than a year | no data | no data | |
| Senior Clinical Development Advisor | no data | no data | no data | |
| Consultant | 8.8yrs | no data | no data |
Experienced Management: 4E2's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 13.8yrs | US$1.80m | 1.77% € 4.3m | |
| Chief Financial Officer | 6yrs | US$993.75k | 1.09% € 2.6m | |
| COO & Director | 10.2yrs | US$872.78k | 0.68% € 1.6m | |
| Independent Chairman of the Board | 10.5yrs | US$353.61k | no data | |
| Member of Scientific Advisory Board | 8.6yrs | no data | no data | |
| Independent Director | 3yrs | US$290.64k | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 6.1yrs | US$286.52k | no data | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Member of Scientific Advisory Board | 6yrs | no data | no data | |
| Chairman of Clinical Advisory Board | less than a year | no data | no data |
Experienced Board: 4E2's board of directors are considered experienced (6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/01/26 07:44 |
| End of Day Share Price | 2026/01/26 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Relmada Therapeutics, Inc. is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Maxim Jacobs | Edison Investment Research |
| Farzin Haque | Jefferies LLC |
| Andrew Tsai | Jefferies LLC |